Neurocrine Biosciences (NBIX) Other Non-Current Liabilities (2010 - 2026)

Neurocrine Biosciences has reported Other Non-Current Liabilities for 17 years, with the latest figure at $260.9 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 43.67% year-over-year to $260.9 million; the trailing twelve-month figure through Mar 2026 stood at $260.9 million (up 43.67% YoY), and the FY2025 full-year result was $219.7 million, up 32.19% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $260.9 million, up from $219.7 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $260.9 million in Q1 2026, with the low at $17.1 million in Q3 2022.
• Historically, Other Non-Current Liabilities has averaged $119.4 million across 5 years, with a median of $120.5 million in 2024.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities retreated 7.51% — and 2023, when it jumped 301.17%.
• Neurocrine Biosciences' Other Non-Current Liabilities stood at $29.7 million in 2022, then surged by 257.91% to $106.3 million in 2023, then surged by 56.35% to $166.2 million in 2024, then soared by 32.19% to $219.7 million in 2025, then climbed by 18.75% to $260.9 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $260.9 million (Q1 2026), $219.7 million (Q4 2025), and $195.7 million (Q3 2025), per Business Quant data.